How big is Alector, Inc.?

As of Jun 18, Alector, Inc. has a market capitalization of 151.99 million and reported net sales of 88.33 million with a net profit of -123.44 million over the latest four quarters. Shareholder's funds are 126.80 million and total assets are 468.30 million as of Dec 24.

As of Jun 18, Alector, Inc. has a market capitalization of 151.99 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 88.33 million, while the sum of Net Profit for the same period is -123.44 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 126.80 million and Total Assets at 468.30 million.

What does Alector, Inc. do?

Alector, Inc. is a clinical-stage biopharmaceutical company specializing in immuno-neurology, with a market cap of approximately $151.99 million and reported net sales of $4 million and a net loss of $40 million for Q1 2025. The company does not pay dividends and has a negative return on equity of -128.14%.

Overview: <BR>Alector, Inc. is a clinical-stage biopharmaceutical company focused on immuno-neurology, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 4 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -40 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 151.99 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -3.55 <BR>Return on Equity: -128.14% <BR>Price to Book: 1.61<BR><BR>Contact Details: <BR>Address: 151 Oyster Point Blvd Ste 300, SOUTH SAN FRANCISCO CA: 94080-1841 <BR>Tel: 1 415 2315660 <BR>Website: https://alector.com

Should I buy, sell or hold Alector, Inc.?

Who are in the management team of Alector, Inc.?

As of March 2022, Alector, Inc.'s management team includes Dr. Tillman Gerngross (Chairman and Co-Founder), Dr. Arnon Rosenthal (CEO and Co-Founder), and several independent directors: Mr. Louis Lavigne, Dr. Paula Hammond, Mr. Terry McGuire, Dr. Richard Scheller, and Mr. David Wehner. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Alector, Inc. includes the following individuals:<BR><BR>- Dr. Tillman Gerngross, who serves as the Chairman of the Board and is a Co-Founder.<BR>- Dr. Arnon Rosenthal, the Chief Executive Officer, Co-Founder, and Director.<BR>- Mr. Louis Lavigne, who is the Lead Independent Director.<BR>- Dr. Paula Hammond, an Independent Director.<BR>- Mr. Terry McGuire, an Independent Director.<BR>- Dr. Richard Scheller, an Independent Director.<BR>- Mr. David Wehner, an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is Alector, Inc. overvalued or undervalued?

As of November 8, 2022, Alector, Inc. is considered overvalued and risky due to its high Price to Book Value and EV to EBIT ratios, significant losses reflected in a negative ROE, and underperformance compared to peers and the S&P 500.

As of 8 November 2022, Alector, Inc. moved from fair to risky, indicating a deterioration in its valuation outlook. The company appears to be overvalued given its financial metrics, particularly with a Price to Book Value of 1.57 and an EV to EBIT of 1.30, which suggest that investors are paying a premium relative to the company's underlying assets and earnings potential. Additionally, the ROCE stands at a high 59.50%, but this is overshadowed by a troubling ROE of -128.14%, reflecting significant losses.<BR><BR>In comparison to its peers, Alector's valuation ratios are concerning; for instance, Avid Bioservices, Inc. has a P/E ratio of -5.2542 while Editas Medicine, Inc. shows a P/E of -1.5909, both indicating a similar risk profile. The overall peer comparison highlights that Alector is not only risky but also underperforming relative to its industry counterparts. Although return data is not available, the lack of positive returns compared to the S&P 500 reinforces the notion that Alector's current valuation may not be justified.

Is Alector, Inc. technically bullish or bearish?

As of September 11, 2025, Alector, Inc. shows a bullish technical trend with strong short-term performance, but mixed indicators and poor long-term returns raise caution.

As of 11 September 2025, the technical trend for Alector, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, and the daily moving averages also indicate a bullish stance. However, the monthly MACD is only mildly bullish, and the Bollinger Bands show a mildly bearish signal on the monthly timeframe. The KST is bullish on the weekly but bearish on the monthly, while the Dow Theory indicates a mildly bullish stance for both weekly and monthly periods. <BR><BR>In terms of performance, Alector has outperformed the S&P 500 over the past week and month, with returns of 9.06% and 46.95%, respectively, compared to 1.05% and 2.33% for the index. However, the longer-term returns are significantly negative, with a 1-year return of -44.50% and a 3-year return of -66.09%. Overall, the current technical stance is bullish, but the strength appears mixed due to the divergence in some indicators and the poor long-term performance.